GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » Capex-to-Operating-Cash-Flow

Advanced Medical Solutions Group (LSE:AMS) Capex-to-Operating-Cash-Flow : 0.39 (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Advanced Medical Solutions Group's Capital Expenditure for the six months ended in Dec. 2024 was £-4.90 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was £12.53 Mil.

Hence, Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2024 was 0.39.


Advanced Medical Solutions Group Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Medical Solutions Group Capex-to-Operating-Cash-Flow Chart

Advanced Medical Solutions Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.21 0.37 0.80 0.45

Advanced Medical Solutions Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 1.16 0.61 0.55 0.39

Competitive Comparison of Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow falls into.


;
;

Advanced Medical Solutions Group Capex-to-Operating-Cash-Flow Calculation

Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-8.744) / 19.489
=0.45

Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-4.901) / 12.527
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Medical Solutions Group  (LSE:AMS) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Advanced Medical Solutions Group Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Medical Solutions Group Business Description

Traded in Other Exchanges
Address
Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
UK-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.